EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Tibor Markus Brunt iD

Addiction · 2026-06 · 121 (6) · 1616-1621

DOI: 10.1111/add.70319 ↗

At a glance

Übersichtsarbeit in Addiction, published online on 2026-01-20. Written by Tibor Markus Brunt. Institution: Department of Psychiatry, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Major MEDLINE topics: Ibogaine, Long QT Syndrome, Hallucinogens, Arrhythmias, Cardiac. Cited 5 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in opioid and cocaine‐dependent individuals, primarily through multiple pharmacological mechanisms; however, ibogaine presents a rare yet clinically significant cardiotoxic risk: QTc prolongation and potentially fatal ventricular arrhythmias such as Torsades des Pointes. Case reports demonstrate that these events occur with therapeutic doses of ibogaine and in individuals without pre‐existing cardiac conditions. A large interindividual variability in CYP2D6 metabolism of ibogaine was shown and might contribute to higher cardiovascular risk in certain individuals. Recent efforts to improve safety of ibogaine include different dosing strategies, cardiovascular monitoring and the development of ibogaine analogues, which retain anti‐addictive efficacy while lacking cardiotoxicity in preclinical models. Future ibogaine‐assisted treatment should be conducted exclusively under controlled medical supervision, with CYP2D6 genotyping and rigorous monitoring of cardiovascular functioning. Future clinical trials should prioritize evaluation of safer analogues and personalized dosing strategies to optimize the benefit–risk profile of this emerging therapy.

Subjects

MeSH terms (MEDLINE)

IbogaineLong QT SyndromeHallucinogensArrhythmias, CardiacTorsades de PointesHumansCytochrome P-450 CYP2D6

Author keywords

QT intervaladdiction treatmentcardiovascularibogainenoribogaineventricular arrhythmias

Substances

IbogaineHallucinogensCytochrome P-450 CYP2D6

Authors and institutions

  • Department of Psychiatry, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

ORCID profiles: Tibor Markus Brunt

Cite

APA

Brunt, T. M. (2026). Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. Addiction, 121(6), 1616-1621. https://doi.org/10.1111/add.70319

Vancouver

Brunt TM. Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. Addiction. 2026;121(6):1616-1621. doi:10.1111/add.70319

BibTeX
@article{Brunt2026,
  author = {Brunt, Tibor Markus},
  title = {Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias},
  journal = {Addiction},
  year = {2026},
  volume = {121},
  number = {6},
  pages = {1616--1621},
  doi = {10.1111/add.70319}
}
Start for free →